Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Igor Bondarenko et al.|The Lancet Oncology|2018Cited by 216
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Caroline Robert, Georgina V. Long et al.|European Journal of Cancer|2017Cited by 171